Technology Insight: Tools for research, diagnosis and clinical assessment of treatment in idiopathic inflammatory myopathies

Nature Clinical Practice Rheumatology

Volumn 3, Issue 5, 2007, Pages 282-290

  Lundberg, Ingrid E ^a   Alexanderson, Helene ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 [4 (2 DIETHYLAMINOETHYLAMINO) 3 NITROPHENYL] 1,4 DIPHENYL 1,2,4 TRIAZOLIUM 3 THIOLATE; AMINO ACID TRANSFER RNA LIGASE; AUTOANTIBODY; CREATINE KINASE; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA;

CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL STUDY; DERMATOMYOSITIS; DIAGNOSTIC PROCEDURE; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; GENE EXPRESSION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LONGITUDINAL STUDY; LUNG; LUNG BIOPSY; MEDICAL TECHNOLOGY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; REVIEW; SKIN BIOPSY; TREATMENT OUTCOME; VALIDATION PROCESS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MICROARRAY ANALYSIS; MUSCLE, SKELETAL; MYOSITIS; PROGNOSIS; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 34248197096     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0479     Document Type: Review

References (61)

1. Arahata K and Engel AG (1984) Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16: 193-208
2. Plotz PH et al. (1995) NIH conference. Myositis: Immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Intern Med 122: 715-724
3. Engel AG and Arahata K (1986) Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 17: 704-721
4. Dalakas MC (1991) Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 325: 1487-1498
5. Dalakas MC and Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362: 971-982
6. Love L et al. (1991) A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70: 360-374
7. Miller FW (1993) Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. JAMA 270: 1846-1849
8. Brouwer R et al. (2001) Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 60: 116-123
9. Timmons AJ et al. (2005) Human muscle gene expression responses to endurance training provide a novel perspective on Duchenne muscular dystrophy. FASEB J 19: 750-760
10. Hoffman EP et al. (2003) New molecular research technologies in the study of muscle disease. Curr Opin Rheumatol 15: 698-707
11. World Health Organization (2001) The International classifications of functioning, disability and health. Geneva: World Health Organization
12. Miller FW et al. (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 40: 1262-1273
13. IMACS website [https://dir-apps.niehs.nih.gov/imacs/ index.cfm?action=home.main]
14. Isenberg DA et al. (2004) International Myositis and Clinical Studies Group (IMACS) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43: 49-54
15. Rider LG et al. (2004) International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 50: 2281-2290
16. Ware JE and Sherbourne CD (1992) The MOS 36-item short-form health survey: Conceptual framework and item selection. Med Care 30 473-483
17. Alexanderson et al. (1999) Safety of a home exercise programme in patients with polymyositis and dermatomyositis. A pilot study. Rheumatology (Oxford) 29: 608-611
18. Alexanderson et al. (2000) The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol 29: 295-301
19. Cherin P et al. (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis. Arthritis Rheum 46: 467-474
20. Danieli MG et al. (2002) Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 61: 37-41
21. Badrising UA et al. (2002) Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 51: 369-372
22. Dalakas MC et al. (2001) A controlled study of intravenous immunoglobulin combined with prednisone in treatment of IBM. Neurology 56: 323-327
23. van der Meulen MFG et al. (2000) Oral pulsed high-dose dexamethasone for myositis. J Neurol 247: 102-105
24. Walter MC et al. (2000) High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 247: 22-28
25. Hengstman GJ et al. (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary results. Eur Neurol 50: 10-15
26. Spector SA et al. (1997) Safety and efficacy of strength training in patients with sporadic inclusion body myositis. Muscle Nerve 10: 1242-1248
27. Wiesinger GF et al. (1998) Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 37: 196-200
28. Wiesinger GF et al. (1998) Benefit of 6 months long-term physical training in polymyositis/dermatomyositis patients. Br J Rheumatol 37: 1338-1342
29. Alexanderson H et a. (2006) Patients with chronic inflammatory myopathies have reduced muscle endurance rather than reduced muscle strength [abstract]. Arthritis Rheum 54 (Suppl): 1639: S658
30. Josefson A et al. (1996) A functional index in myositis. J Rheumatol 23: 1380-1384
31. Vencovsky J et al. (2000) Cyclosporine A versus methotrexate in treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29: 95-102
32. Heikkilä S et al. (2001) Rehabilitation in myositis. Physiotherapy 87: 301-309
33. Alexanderson H et al. (2006) Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum 55: 114-122
34. Newcomer KL et al. (1993) Validity and reliability of the timed-stands test for patients with rheumatoid arthritis and other chronic diseases. J Rheumatol 20: 21-27
35. Agarwal S et al. (2006) Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis. Rheumatology (Oxford) 45: 874-879
36. Marie I et al. (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47: 614-622
37. Fathi M et al. (2004) Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis 63: 297-301
38. Mayberry JP et al. (2000) Thoracic manifestations of systemic autoimmune diseases: Radiographic and high-resolution CT findings. Radiographics 20: 1623-1635
39. Wilkes MR et al. (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52 2439-2346
40. Barthel DW and Mahoney FI (1965) Functional evaluation; the Barthel Index. Md State Med J 14: 61-65
41. Varju C et al. (2003) The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil 17: 83-87
42. Alexanderson H et al. (2002) Development of the myositis activities profile - validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol 29: 2386-2392
43. Alexanderson H et al.: Safety and benefits of an intensive resistive exercise program in patients with stable, inactive polymyositis or dermatomyositis. Arthritis Rheum, in press
44. Henriksson KG (1979) 'Semi-open' muscle biopsy technique. A simple outpatient procedure. Acta Neurol Scand 59: 317-323
45. Dorph C et al. (2001) Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol 28: 1591-1599
46. Lundberg I et al. (2000) Decreased expression of interleukin-1alpha-beta and cell adhesion molecules in muscle tissue following corticosteroid treatment in polymyositis and dermatomyositis. Arthritis Rheum 43: 336-348
47. Ulfgren AK et al. (2004) Down-regulation of the abberant expression of the inflammation mediator High Mobility Group Box Chromosomal Protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 50: 1586-1594
48. Nyberg P et al. (2000) Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol 27: 940-948
49. Dalakas MC (1996) Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 104 (Suppl 1): 55-60
50. Nagaraju K et al. (2005) Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction. Arthritis Rheum 52: 1824-1835
51. Greenberg S et al. (2005) Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57: 664-678
52. + children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol 168: 4154-4163
53. Raju R et al. (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: Effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 128 1887-1896
54. Hofbauer M et al. (2003) Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci USA 100: 4090-4095
55. Greenberg S et al. (2005) Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 65: 1782-1787
56. Englund P et al. (2002) Interleukin-1 alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum 46: 1044-1455
57. van der Pas J et al. (2004) Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J Neurol Neurosurg Psychiatry 75: 136-139
58. Civatte M et al. (2003) Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol 29: 546-552
59. Dorph C et al. (2006) Patient reported symptomatic muscle weakness is independent of inflammation in muscle tissue from patients with polymyositis and dermatomyositis. Ann Rheum Dis 65: 1565-1571
60. Park JH et al. (1998) Analysis of 31P MR spectroscopy data using artificial neural networks for longitudinal evaluation of muscle diseases: Dermatomyositis. NMR Biomed 11: 245-256
61. Miller FW et al. (1990) Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 85: 468-475